Equities analysts expect that Endo International PLC (NASDAQ:ENDP) (TSE:ENL) will report sales of $696.72 million for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Endo International’s earnings, with estimates ranging from $672.80 million to $713.63 million. Endo International posted sales of $714.70 million in the same quarter last year, which suggests a negative year-over-year growth rate of 2.5%. The company is expected to announce its next earnings report on Wednesday, August 14th.
According to Zacks, analysts expect that Endo International will report full-year sales of $2.87 billion for the current fiscal year, with estimates ranging from $2.83 billion to $2.89 billion. For the next year, analysts expect that the business will report sales of $2.88 billion, with estimates ranging from $2.63 billion to $3.00 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Endo International.
Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Thursday, May 9th. The company reported $0.53 earnings per share for the quarter, topping analysts’ consensus estimates of $0.42 by $0.11. The company had revenue of $720.00 million for the quarter, compared to analysts’ expectations of $692.31 million. Endo International had a negative net margin of 18.35% and a negative return on equity of 199.18%. The firm’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter last year, the company earned $0.67 earnings per share.
A number of equities analysts recently weighed in on ENDP shares. ValuEngine upgraded Endo International from a “sell” rating to a “hold” rating in a research report on Monday, February 4th. Zacks Investment Research downgraded Endo International from a “hold” rating to a “sell” rating in a research note on Thursday, February 7th. Piper Jaffray Companies reaffirmed a “hold” rating on shares of Endo International in a research note on Friday, March 1st. Leerink Swann downgraded Endo International from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 5th. Finally, Svb Leerink downgraded Endo International from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 5th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating and six have assigned a buy rating to the company’s stock. Endo International has a consensus rating of “Hold” and an average target price of $14.88.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ENDP. Oregon Public Employees Retirement Fund raised its position in Endo International by 1.8% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 77,330 shares of the company’s stock valued at $621,000 after purchasing an additional 1,397 shares during the last quarter. Piedmont Investment Advisors Inc. grew its stake in Endo International by 3.5% in the fourth quarter. Piedmont Investment Advisors Inc. now owns 47,942 shares of the company’s stock valued at $350,000 after acquiring an additional 1,607 shares during the period. Mason Street Advisors LLC grew its stake in Endo International by 3.4% in the first quarter. Mason Street Advisors LLC now owns 64,141 shares of the company’s stock valued at $515,000 after acquiring an additional 2,134 shares during the period. Neuburgh Advisers LLC grew its stake in Endo International by 13.9% in the fourth quarter. Neuburgh Advisers LLC now owns 24,860 shares of the company’s stock valued at $181,000 after acquiring an additional 3,036 shares during the period. Finally, Comerica Bank grew its stake in Endo International by 2.1% in the first quarter. Comerica Bank now owns 198,605 shares of the company’s stock valued at $1,650,000 after acquiring an additional 4,001 shares during the period. 90.95% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ ENDP traded down $0.15 on Friday, reaching $5.97. The company had a trading volume of 29,817 shares, compared to its average volume of 3,280,272. The stock has a market cap of $1.45 billion, a PE ratio of 2.07 and a beta of 1.12. Endo International has a 1 year low of $5.96 and a 1 year high of $18.50.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.